RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.CTXR

Market cap
$90.67M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2015		Sep 30,
2016		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
Revenues----------
Research and development---237991218
General and administrative12,18716,24619,139946,61346681012
Stock-based compensation – general and administrative---486,271732,151779,701715,983803,26114
Total Operating Expenses41,13760,75588,873371416182433
Operating Loss-25,637-19,618-28,118-3,229,929-7,449,291-13,789,143-15,598,361-17,710,685-23,531,894-33,316,045
Interest income------52,66068,066261,825251,399
Gain on forgiveness of note payable - Paycheck Protection Program and accrued interest-----450,000--166,557-
Other income-------110,20759,917-
Interest expense-3,092-7,5008,99415,83816,44315,67310,839-
Total Other Income, Net---------251,399
Loss before Income Taxes-26,341-22,006-31,369-2,902,268-8,295,698-12,536,63816-17,548,085--33,064,646
Income tax expense---------576,000
Net Loss-26,341-22,006-31,369-2,902,268-8,295,698-12,536,638-15,562,144-17,548,085-23,054,434-33,640,646
Net Loss Applicable to Common Stockholders---------24,505,310-33,640,646
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share)----------0.23